CAS 2068119-11-7

S18-000003

CAS: 2068119-11-7

S18-000003

Purity: ≥98%

Molecular weight: 518.55g/mol

Ref: 54-BUP09206

S18-000003

CAS: 2068119-11-7

S18-000003: Oral retinoic acid receptor gamma-t inhibitor, IC50 29 nM, reduces IL-17 production.

Formula: C₂₆H₂₅F₃N₂O₄S

Purity: 99.24% - 99.31%

Color and Shape: Solid

Molecular weight: 518.55

Ref: TM-T16832

S18-000003

CAS: 2068119-11-7

Pro-inflammatory cytokines are a class of proteins that are integral to the immune response. The pro-inflammatory cytokine IL-17 is a crucial player in autoimmune disorders, as it promotes inflammation and protects against invading bacteria and fungi. IL-17 also has an important role in the development of cardiac disease, as it stimulates inflammation in heart tissue and can lead to cardiac damage. It is believed that the inhibition of IL-17 could provide new therapeutic strategies for autoimmune diseases and inflammatory diseases. S18-000003 is a synthetic drug that targets IL-17 production by binding to the retinoic acid receptor (RAR) beta, which is the target for retinoic acid synthesis. This drug has been shown to reduce the production of pro-inflammatory cytokines such as IL-17, providing a potential therapeutic strategy for autoimmune disorders and inflammatory diseases.

Formula: C₂₆H₂₅F₃N₂O₄S

Purity: Min. 95%

Molecular weight: 518.5 g/mol

Ref: 3D-THD11911